Kornimate/medical-research-clean huggingface dataset:
immune cell subgroups in covid 19 patients

Conditions: Covid19

Summary: covid-19, spreading rapidly all over the world, causes serious morbidity and mortality. in severe covid-19 infections, after pulmonary inflammation, cardiovascular organ failure, cytokine storm, hemophagocytosis, septic shock, develops due to uncontrolled hypoxia, and isolated organ failure turns into multi-organ failure. it is noteworthy that it causes lymphopenia in patients. in studies conducted, the effects of covid-19 on the immune system were evaluated with limited parameters. in addition, no study evaluating the effect of this disease on the immune system has been published in our country.

the causative agent of coronavirus 2019 (covid-19) disease, which started in wuhan province of china in december 2019, was severe acute respiratory failure syndrome coronavirus 2 (sars-cov-2), which quickly spread all over the world and caused a pandemic. covid-19 can cause death with symptoms such as fever, cough, muscle pain, shortness of breath, and pneumonia (1). pulmonary pathology of covid-19 is diffuse alveolar damage, focal reactive hyperplasia of pneumocytes with patchy inflammatory cells, intravascular thrombosis, monocyte, macrophage and lymphocyte infiltration into pulmonary spaces. severe infiltration of pulmonary tissue affects alveolar gas exchange. in addition, cardiovascular morbidity, tachyarrhythmia and thromboembolic events are observed in 1/5 of the hospitalized patients with troponin elevation, which is closely related to mortality. in severe covid-19 infections, after pulmonary inflammation, cardiovascular organ failure, cytokine storm, hemophagocytosis, septic shock, develops due to uncontrolled hypoxia, and isolated organ failure turns into multi-organ failure. it is noteworthy that it causes lymphopenia in patients. in the studies conducted, the effects of covid-19 on the immune system and the determination of cell subgroups were performed with limited parameters. no studies have been conducted on pdl-1, one of the immune control points. in addition, no study evaluating the effect of this disease on the immune system with wide parameters has been published in our country. we aimed to study cd3 (+) lymphocytes, cd4 (+) lymphocytes, cd 8 (+) lymphocytes, cd 3(-)/cd16 (+) nk cell ratio, cd14 (+) lymphocytes, and hla-dr positivity on cd14 (+) cells at covid-19 and healthy volunteers.

Eligibility criteria:
inclusion criteria: * patients with covid 19 pcr (+) results exclusion criteria: * cancer patients * patients with known immunodeficiency * pregnancy

Keywords: t helper cell t cytotoxic cell monocyte nk cell
extension to a study on the efficacy and safety of vildagliptin compared to rosiglitazone in drug naive patients with type 2 diabetes

Conditions: Diabetes Mellitus, Type 2

Summary: this is an 80-week extension to a study to assess the safety and effectiveness of vildagliptin, an unapproved drug, compared to rosiglitazone in lowering overall blood glucose levels in people with type 2 diabetes who have not previously been treated with drug therapy to lower their blood sugar. the purpose of the extension study is to gather data on the long-term safety and effectiveness of vildagliptin in people with type 2 diabetes.


Eligibility criteria:
inclusion criteria: * only patients successfully completing study claf237a2327 are eligible * written informed consent * ability to comply with all study requirements exclusion criteria: * premature discontinuation from study claf237a2327 * other protocol-defined exclusion criteria may apply

Keywords: type 2 diabetes vildagliptin
children's automated respiration monitor (charm) for child pneumonia diagnosis by community health workers in mali

Conditions: Acute Respiratory Infection

Summary: the primary objective of this study is to estimate the impact of a self-monitoring tool (charm), used as a teaching/monitoring device, on the chws respiratory rate counting accuracy when assessing children under the age of 5 years with suspected pneumonia symptoms.

methodology: the study is designed as a community based, cluster randomized, pragmatic, intervention trial. it will be conducted within the existing 2016-2020 project structure. specifically, the intervention will evaluate the potential of the charm device to improve chws competency in counting respiratory rate and diagnose pneumonia more accurately in children under 5 years presenting with symptoms in remote areas. intervention group a - community health workers (chws) (basic training in chw curriculum, charm training and 8-month application of the charm device, self-monitoring, direct observation and review of chw routine monthly reports and drug supply sheets): 8 months, march- november 2018. intervention group b - community health workers (basic training in chw curriculum, charm training and 4-month application of the charm device, self-monitoring, direct observation and review of chw routine monthly reports and drug supply sheets): 8 months,march- november 2018. control group c - community health workers (basic training in chw curriculum, direct observation and chw routine monthly reports and drug supply sheets): 8 months, march- november 2018. chw and field monitor in-depth interviews - november 2018 data analysis and report writing - december 2018-january 2019

Eligibility criteria:
inclusion criteria: * • be currently providing iccm services on a full-time basis to the populations they are serving. * have completed the malian ministry of health basic community health care worker training provided as part of the 2016-2020 strengthening maternal, newborn and child health project. * are using a device (a respiratory timer) as part of their basic moh training package, or have a cell phone to use to count the respiratory rates of children under five with suspected symptoms of pneumonia. * be willing to participate in a trial to study the impact of using charm as a self-monitoring tool to improve the capacity to detect pneumonia. exclusion criteria: * • chws in conflict ridden geographical areas within the district or not, providing consistent services on a full-time basis to the populations they are serving. * chws not willing to participate in the trial. * chws who do not have a device (watch, respiratory timer or cell phone) to support measurement of respiratory rates and who are not routinely counting respiratory rate to diagnose suspected pneumonia. * chws who did not complete the moh basic training for chws provided through the 2016-2020 strengthening maternal, newborn and child health program

Keywords: charm community health worker
silymarin for the prevention of atrial fibrillation after cardiac surgery

Conditions: Atrial Fibrillation New Onset

Summary: the study is a prospective, randomized, controlled trial to assess the effects of silymarin on the occurrence of postoperative atrial fibrillation after coronary artery bypass graft surgery.

postoperative atrial fibrillation (poaf) is a frequent complication after coronary artery bypass graft (cabg) surgery and is associated with increased mortality. so far, the effects of various drugs and supplements on the occurrence of postoperative atrial fibrillation (poaf) have been studied, but no one has looked into the effect of silymarin on the occurrence of poaf. the study is designed as a prospective, randomized, controlled trial to assess the effects of silymarin on the occurrence of postoperative atrial fibrillation after cabg surgery. a total of 160 patients of both sexes scheduled for elective cabg surgery using cardiopulmonary bypass (cpb) will be included. they will be randomized into two groups (experimental and control) with 80 patients each. subjects in the experimental group will receive 400 mg of silymarin three days preoperatively, while subjects in the control group will receive standard therapy. the occurrence of poaf after cabg surgery will be the primary outcome, which will be defined as any dysrhythmia that represents the ecg characteristics of atrial fibrillation lasting at least 30 s on a rhythm strip or 12-lead ecg. secondary outcomes will include postoperative values of inflammation markers, length of stay in the icu, length of hospitalization, and occurrence of postoperative complications (pericardial effusion, stroke, in-hospital death).

Eligibility criteria:
inclusion criteria: * scheduled for elective cabg surgery using cardiopulmonary bypass * first cardiac surgery * left ventricular ejection fraction \> 35% * less than moderate mitral regurgitation exclusion criteria: * preoperative atrial fibrillation * previous history of interventionally treated arrhythmias * end-stage renal disease requiring hemodialysis * chronic inflammatory and neoplastic diseases

Keywords: cardiac surgery postoperative atrial fibrillation silymarin
phase 3 trial of ncx 470 vs. latanoprost in subjects with open-angle glaucoma or ocular hypertension

Conditions: Open Angle Glaucoma; Ocular Hypertension

Summary: the objective of this clinical study is to evaluate the safety and efficacy of ncx 470 ophthalmic solution in lowering intraocular pressure (iop) in patients with ocular hypertension or open-angle glaucoma. in the adaptive dose selection phase of the trial, subjects will be randomized in a 1:1:1 ratio to one of two doses of ncx 470 (0.065% or 0.1%) or to latanoprost 0.005%. following the selection of one dose of ncx 470, subjects will be randomized in a 1:1 ratio to the chosen dose of ncx 470 or to latanoprost 0.005%.


Eligibility criteria:
inclusion criteria: * diagnosis of open-angle glaucoma or ocular hypertension in both eyes * qualifying iop at 3 time points through the day at 2 visits following washout of iop-lowering medication, if applicable * qualifying best-corrected visual acuity in each eye * ability to provide informed consent and follow study instructions exclusion criteria: * narrow anterior chamber angles or disqualifying corneal thickness in either eye * clinically significant ocular disease in either eye * previous complicated surgery or certain types of glaucoma surgery in either eye * incisional ocular surgery or severe trauma in either eye within the past 6 months * uncontrolled systemic disease
a comparison of fdg-pet versus mri based target volume delineation in glioblastoma and the role of fdg-pet/ct in the alteration of mri based target volumes.

Conditions: Glioblastoma

Summary: hypothesis and sample size the tumor delineated by fdg-pet is significantly different from the delineation achieved by mr t1 contrast weighted images in glioblastoma; expecting a standard error of 12.5 % (a confidence interval of 25%), with a confidence level set at 95%, a sample size of 15 patients would be accrued in the study.


Eligibility criteria:
inclusion criteria: 1. post operative patients of documented high grade gliomas (grade iii and iv) 2. patients who have not undergone any previous irradiation to brain. 3. performance scale as defined by ecog ps 0-3 exclusion criteria: 1. patients who are diabetic. 2. patients who are pregnant. 3. any documented contrast allergy to the agents used for imaging. 4. patients who are unable to comprehend or cooperate effectively for treatment planning.

Keywords: glioblastoma fdg-pet mri
nicotine influence on the retina following the use of electronic cigarette

Conditions: Electronic Cigarette Use; Retina; Change

Summary: the marketing of electronic cigarettes (e-cigarettes) in 2003 was initially intended to present a healthier alternative to smokers. subsequently, it became an extremely widespread fashion phenomenon, especially among young people. it thus contributes to attracting new consumers thanks to its modern and technological presentation, combined with a panoply of captivating fragrances. in 2014, the fda still does not recognize this practice as a substitute for smoking intended to limit it, and several recent studies have demonstrated the potential harmful effects of e-cigarettes on health. indeed, the latter also have pulmonary effects reminiscent of those of the original cigarette, namely breathing difficulties or even lung inflammation. in addition, a potential impact on the vascular system has recently been highlighted by the use of these e-cigarettes. thus, their components can lead to vascular changes in the reactivity of blood vessels, an increase in blood pressure or even endothelial dysfunction and vascular and cerebral oxidative stress. the aim of this study is to detect these phenomena at the level of the retinal circulation, window of the central nervous system, in order to be able to confirm the acute vascular impacts of the use of an e-cigarette. in addition, the vascular and metabolic impacts due to the potential toxicity of the other components of these e-cigarettes could be investigated. finally, the comparison between patients who are smokers and occasional smokers will provide a better understanding of the different acute and chronic effects of nicotine.


Eligibility criteria:
inclusion criteria: * subject between 18 and 40 years old. * the subject must be a regular smoker (more than 1 cigarette per day for 2 years) or be an occasional smoker (between 1 and 15 cigarettes in his life). * the subject must be able to sign a free and informed consent, and to follow the instructions. * complete visual examination within the last 5 years. exclusion criteria: * narrow iridocorneal angles. * inadequate or contraindicated pupil dilation. * insufficient visual fixation. * ametropia greater than -6 and +6 δ. * known hypersensitivity or allergy to any component of the ophthalmic formulation used, including benzalkonium chloride (preservative) and components of the vaping liquid. * eye trauma or eye surgery in the last 6 months. * evidence of present or recent infection or inflammation in both eyes. * the use of ocular or systemic medication 30 days prior to the study. * presence of ocular pathology (corneal oedema, severe keratoconjunctivitis sicca, advanced cataract, retinopathy, glaucoma). * systemic disease (uncontrolled diabetes, myasthenia gravis...) or pulmonary, cardiac, hepatic, renal, endocrine problems. * history of epilepsy and psychiatric: schizophrenia, bipolarity, anxiety, depression. * being pregnant or breastfeeding. * history of alcohol abuse. * history of drug or psychotropic use.
micronutrients in critically ill patients

Conditions: Nutrition; Critical Illness; Vitamin Supplementation

Summary: nutritional support is an important component of modern critical care. the practice of vitamin and micronutrient supplementation is variable and official guidelines are not consistent. the primary objective of this observational study is to investigate the clinical practice of micronutrient supplementation during critical illness and to explore the factors underpinning clinical decisions.

nutritional support is an integral component of modern critical care. malnutrition is common, but measurement of serum concentrations of most vitamins and micronutrients does not form part of routine care for most critically ill adults in the uk. when measured in a research setting, a large proportion of critically ill patients have low serum concentrations of many essential nutrients. nutrient deficiency is associated with adverse outcomes, including delirium and increased mortality. to date, it is unclear whether there is a role for micronutrient supplementation in critically ill patients. official guidelines from the european society of parenteral and enteral nutrition (espen), american society of parenteral and enteral nutrition (aspen), german intensive care society and kidney disease improving global outcome (kdigo) vary and are contradictory to some extent. additionally, vitamins b1 and c have been administered as an intervention in the treatment of septic shock and other disease states, but methodological flaws with such studies have left many clinicians with equipoise over the place of vitamin and micronutrients in clinical practice. there is a need for a well designed, adequately powered intervention study. in preparation, we would like to explore current practice and decision making of doctors, pharmacists and dieticians who are directly involved in prescribing nutritional support. the primary objective of this observational study is to investigate the clinical practice of micronutrient supplementation during critical illness and to explore the factors underpinning clinical decisions.

Eligibility criteria:
inclusion criteria: * healthcare professional who is involved in prescribing vitamins or micronutrients to critically ill patients in the icu exclusion criteria: * none

Keywords: micronutrient supplementation vitamins
single dose study of gw856553 on a protein that is an indicator for rheumatoid arthritis (ra)

Conditions: Arthritis, Rheumatoid

Summary: this study is designed to compare a range of doses of gw856553 versus placebo on the biomarkers associated with rheumatoid arthritis


Eligibility criteria:
inclusion criteria: * must have a diagnosis of ra according to the revised 1987 criteria of the american college of rheumatology. * must have 3 or more swollen or 3 or more tender/painful joints at screening. * must be on stable weekly methotrexate (2.5mg-25mg) for at least eight weeks prior to screening. exclusion criteria: * must not be morbidly obese.

Keywords: gw856553 biomarkers crp rheumatoid arthritis
pilot study of short-course glucocorticoids and rituximab for treatment of anca-associated vasculitis

Conditions: Granulomatosis With Polyangiitis; Microscopic Polyangiitis

Summary: the purpose of this pilot study is to test whether an 8-week course of glucocorticoids, combined with rituximab, is effective in treating anca-associated vasculitis.

the primary aim of this pilot study is to examine whether an 8 week course of glucocorticoids, in combination with rituximab, is effective in inducing and maintaining disease remission for up to 6 months in a subset of patients with anca-associated vasculitis (aav) who have a more favorable prognosis. this pilot study will enroll 20 patients with active aav. close patient follow-up will insure that any patients who require courses of glucocorticoids longer than two months will receive longer therapy, if appropriate for their well-being.

Eligibility criteria:
inclusion criteria: * patients ages 18-85 years old * diagnosis of gpa or mpa according to the definitions of the chapel hill consensus conference * new diagnosis or disease flare with a birmingham vasculitis activity score/wegener's granulomatosis (bvas/wg) of \> 3 exclusion criteria: * renal disease in patients with pr3-anca as defined by any of the following: * urinary red blood cell casts * biopsy-proven glomerulonephritis * increase in serum creatinine of \>30% over baseline * severe renal disease in patients with mpo-anca as defined by both of the following: * urinary red blood cell casts or biopsy-proven glomerulonephritis * estimated glomerular filtration rate \< 30 ml/min/1.73m2 * diffuse alveolar hemorrhage requiring ventilatory support * gc treatment for longer than 14 days prior to enrollment unless patient has been on a stable maintenance dose of prednisone at the time of the flare * daily oral cyclophosphamide within 1 month prior to enrollment * completed a remission induction course of cyclophosphamide or rituximab within 4 months of enrollment * hepatitis b infection * hiv infection * history of anti-gbm disease * other uncontrolled disease, including drug and alcohol abuse, that may interfere with the study * pregnancy or breastfeeding * history of severe allergic reactions to human or chimeric monoclonal antibodies
treatment effect according to timing of administration of dwp14012 40 mg

Conditions: Erosive Esophagitis

Summary: the primary objective of this study is to establish noninferiority of efficacy of dwp14012 (40 mg once daily) based on timing of administration.

subjects will provide written informed consent for study participation and then undergo appropriate screening. subjects who meet the inclusion criteria and none of the exclusion criteria will be randomized in a 1:1 ratio to either before meal group or after meal group. subjects will be stratified into two groups according to los angeles classification grades (la grades) a/b or c/d, as determined by upper gastrointestinal (gi) endoscopy.

Eligibility criteria:
inclusion criteria: * adults between 19 and 75 years old based on the date of written agreement * those who have been diagnosed with erosive esophagitis of la grade a-d on the upper gastrointestinal endoscopy * those who experienced symptoms of heartburn or acid regurgitation within the last 7 days exclusion criteria: * those who have undergone gastric acid suppression or gastric, esophageal surgery * those who with clinically significant liver, kidney, nervous system, respiratory, endocrine, hematologic, cardiovascular, urinary system disease
upper limb functional index

Conditions: Upper Limb Function; Upper Limb Pain; Upper Limb; Injury, Superficial, Multiple; Upper Limb Rehabilitation

Summary: to translate and validate the upper limb functional index into albanian for use in the albanian-speaking population.

the cross-cultural adaptation will be carried out in accordance with the internationally recommended methodology, following the guidelines: translation, back-translation; dissemination of questionnaires and data collection and analysis.

Eligibility criteria:
inclusion criteria: * shoulder pain * arm pain * myofascial pain * muscular pain * trigger points * arthritis exclusion criteria: * tumor * metabolic disease * neurologic conditions
rtms improves functions in spinocerebellar ataxia

Conditions: Transcranial Magnetic Stimulation; Spinocerebellar Ataxias

Summary: spinocerebellar ataxia (sca) is a group of inherited brain disorders. sca often result in poor limb coordination. this study aims to discover the effects of repeated transcranial magnetic stimulation (rtms) on balance \& gait in sca. the hypothesis of this study is that rtms might improve sca limb functional performance.

rtms has been shown that improves walking speed and balance performance, however, the optimal treatment protocols have not been approved. past studies used different frequencies 1 hz, 5 hz and 10 hz to improve functional performance. the results might be affected by the types of sca. in this study, we will focus on the sca type 3 to assess the effects on high frequency (10 hz) of rtms intervention.

Eligibility criteria:
inclusion criteria: * sca type 3 * independently walk with/without an assistive device * sara greater than 3 exclusion criteria: * epilepsy history * unstable blood pressure * brain trauma * alcoholism, drug abuse, antipsychotics drug use * metallic hardware (e.g. - cochlear implants, brain stimulators or electrodes, aneurysm clips) anywhere in head. * dementia, depression

Keywords: rtms sca